-transparent.png){kind=logo}
Although most circulating T cells in normal subjects express both CD3 and CD5 antigens on the cell surface, a small number lack the CD5 antigen. Recipients of allogeneic bone marrow transplants develop increased numbers of CD3+ CD5- cells, particularly those who develop graft versus host disease (GVHD). This CD3+ CD5- population may rise transiently in patients who have received an autologous bone marrow transplant (BMT) and in patients following completion of intensive chemotherapy for acute myeloid leukaemia (AML). These findings suggest that these CD3+ CD5- cells are a normal component of the regenerating lymphoid system after BMT or chemotherapy.
Related Publications
P J McKay, and
A McLaren, and
L M Andrews, and
N P Lucie
January 1989,
Nihon Gan Chiryo Gakkai shi,
P J McKay, and
A McLaren, and
L M Andrews, and
N P Lucie
January 1986,
Oncology,
P J McKay, and
A McLaren, and
L M Andrews, and
N P Lucie
March 1986,
Transplantation,
P J McKay, and
A McLaren, and
L M Andrews, and
N P Lucie
October 1989,
Lancet (London, England),
P J McKay, and
A McLaren, and
L M Andrews, and
N P Lucie
January 1988,
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
P J McKay, and
A McLaren, and
L M Andrews, and
N P Lucie
January 1990,
Bone marrow transplantation,
P J McKay, and
A McLaren, and
L M Andrews, and
N P Lucie
March 1983,
Clinical and experimental immunology,
P J McKay, and
A McLaren, and
L M Andrews, and
N P Lucie
January 1981,
Acta haematologica,
P J McKay, and
A McLaren, and
L M Andrews, and
N P Lucie
October 1983,
Experimental hematology,
P J McKay, and
A McLaren, and
L M Andrews, and
N P Lucie
September 1984,
Cancer,
